Which medication is classified as an NDRI?

Bupropion is classified as a norepinephrine-dopamine reuptake inhibitor (NDRI). This classification reflects its unique mechanism of action, as it primarily acts by inhibiting the reuptake of norepinephrine and dopamine in the brain. As a result, it helps increase the levels of these neurotransmitters, which can alleviate symptoms of depression and assist in smoking cessation.

Bupropion differs from other common antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), in that it does not primarily affect serotonin levels. This makes it an important option for patients who may not tolerate SSRIs well or for whom SSRIs are ineffective. Additionally, bupropion's stimulant-like effects can be beneficial for patients experiencing fatigue or sluggishness due to depression.

In contrast, the other medications listed—sertraline, fluoxetine, and paroxetine—are all classified as SSRIs. These medications work mainly by increasing serotonin availability in the brain, which is a different approach compared to the NDRI mechanism of bupropion. This distinction is crucial for tailoring treatments to individual patient needs and potential side effects.